Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 5-Ethynyluracil; 5-EU; 776C85; ADH 300004; GW 776C85

Latest Information Update: 17 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Adherex Technologies; Fennec Pharmaceuticals; GlaxoSmithKline
  • Class Antineoplastics; Chemosensitisers; Pyrimidinones; Small molecules
  • Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer
  • Discontinued Colorectal cancer; Erythrodysaesthesia; Head and neck cancer; Liver cancer; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Sep 2014 Adherex is now called Fennec Pharmaceuticals
  • 09 Aug 2013 Eniluracil is available for licensing as of 09 Aug 2013. www.adherex.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top